Press release
Nov 22, 2012

Seebri® Inhalation Capsules 50 mcg, a new once-daily treatment for the symptoms of COPD, launched in Japan by licensing partner

Tokyo, Japan – 22 November 2012: Sosei Group Corporation (“Sosei”; TSE Mothers Index: 4565) confirms that Novartis Pharma K.K. launched Seebri® Inhalation Capsules 50 mcg (“Seebri®”; glycopyrronium bromide), a new maintenance treatment to relieve symptoms in patients with chronic obstructive pulmonary disease (COPD, emphysema), in Japan today. Seebri® is a once–daily long-acting muscarinic antagonist (LAMA) therapy based on delivery with the Breezhaler® device. Seebri® provides 24-hour bronchodilation and has shown to improve respiratory function in COPD patients rapidly after the first inhalation.